NBRVF (Nabriva Therapeutics) Common Stock: $0.03 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NBRVF Nabriva Therapeutics PLC NBRVF
12 GF Score
Price $0.00
View Full Analysis

What is Nabriva Therapeutics Common Stock?

Nabriva Therapeutics NBRVF 12 Common Stock is $0.03 Mil as of Jun. 2023. GuruFocus rates NBRVF with a GF Score™ of 12/100.

Nabriva Therapeutics's quarterly common stock stayed the same from Dec. 2022 ($0.03 Mil) to Mar. 2023 ($0.03 Mil) and stayed the same from Mar. 2023 ($0.03 Mil) to Jun. 2023 ($0.03 Mil).

Nabriva Therapeutics's annual common stock declined from Dec. 2020 ($0.21 Mil) to Dec. 2021 ($0.02 Mil) but then increased from Dec. 2021 ($0.02 Mil) to Dec. 2022 ($0.03 Mil).

Nabriva Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Nabriva Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nabriva Therapeutics Common Stock Chart

Nabriva Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.67 0.10 0.21 0.02 0.03

Nabriva Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.03 0.03 0.03 0.03
NBRVF
12GF Score
Nabriva Therapeutics PLC NBRVF
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nabriva Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.03 Mil mean?
Nabriva Therapeutics (NBRVF) has a Common Stock of $0.03 Mil as of Jun. 2023. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Nabriva Therapeutics and its competitors.
Is Nabriva Therapeutics' Common Stock too high?
Nabriva Therapeutics' current Common Stock is $0.03 Mil. Overall, Nabriva Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nabriva Therapeutics' Common Stock compare to BXRX and INM?
Nabriva Therapeutics' Common Stock of $0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Nabriva Therapeutics and its competitors. Nabriva Therapeutics's current Common Stock is $0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nabriva Therapeutics stock overvalued right now?
Nabriva Therapeutics (NBRVF) has a current Common Stock of $0.03 Mil. The current Common Stock is $0.03 Mil. Nabriva Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Nabriva Therapeutics (NBRVF), the current Common Stock is $0.03 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nabriva Therapeutics Business Description

Address Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. The company is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
12GF Score

Get the complete analysis for NBRVF

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price